Selected articles
Articles for label Petruželka Luboš are displayed.. Show all articles
Which tumors are really rare?
04/2018 Prof. MUDr. Luboš Petruželka, CSc.
Precision oncology implies customizing treatment for each individual and cancer based on unique molecular and biologic characteristics. In the pregenomic era cancers are classified based on tumor site and histology. In the upcoming genomic era malignant diseases are reclassified based on molecular and biologic characteristics which results in increased number of cancer types. In the future, more and more identifiers of tumor diversity will be defined and the end of the pregenomic era of rare tumors can be expected.
ENTIRE ARTICLE
Precision oncology implies customizing treatment for each individual and cancer based on unique molecular and biologic characteristics. In the pregenomic era cancers are classified based on tumor site and histology. In the upcoming genomic era malignant diseases are reclassified based on molecular and biologic characteristics which results in increased number of cancer types. In the future, more and more identifiers of tumor diversity will be defined and the end of the pregenomic era of rare tumors can be expected.
Cellular mechanisms and signal pathways transduction in pancreatic cancer
01/2018 As. RNDr. Ing. Libor Staněk, PCTM; prof. MUDr. Robert Gurlich, DrSc.; doc. MUDr. Petra Tesařová, CSc.; Mgr. Zdeněk Musil; prof. MUDr. Luboš Petruželka, CSc.
Pancreatic cancer is one of the most severe types of human tumors. It is the second most common cause of cancer deaths in the world. Worldwide, more than 300,000 new diseases are diagnosed annually and approximately the same number of patients die of this disease. In 2015, the incidence of 20/100,000 inhabitants in the Czech Republic was the second highest in the world. Despite all the advances in modern oncology treatment, the long-term survival of people with this type of malignant growth is rather exceptional. Therefore, attention is focused on the genetic causes of this cancer. Essentially, this is a genetic disease where the exact sequence of somatic DNA mutations with a multistage process is known, with the cumulative effect of mutations obtained in both coding and regulatory genes, changes in ploidy, gene amplification, structural rearrangement, deletion or loss of heterozygosity. The most frequent mutations occur in the protooncogenes of K-ras and tumor suppressor genes p16, p53, BRCA2 and DPC4/SMAD4, leading to malignant change of the epithelium of leads.
ENTIRE ARTICLE
Pancreatic cancer is one of the most severe types of human tumors. It is the second most common cause of cancer deaths in the world. Worldwide, more than 300,000 new diseases are diagnosed annually and approximately the same number of patients die of this disease. In 2015, the incidence of 20/100,000 inhabitants in the Czech Republic was the second highest in the world. Despite all the advances in modern oncology treatment, the long-term survival of people with this type of malignant growth is rather exceptional. Therefore, attention is focused on the genetic causes of this cancer. Essentially, this is a genetic disease where the exact sequence of somatic DNA mutations with a multistage process is known, with the cumulative effect of mutations obtained in both coding and regulatory genes, changes in ploidy, gene amplification, structural rearrangement, deletion or loss of heterozygosity. The most frequent mutations occur in the protooncogenes of K-ras and tumor suppressor genes p16, p53, BRCA2 and DPC4/SMAD4, leading to malignant change of the epithelium of leads.